Gentiana macrophylla pall is used in Mongolian and Tibetan hospitals for various diseases such as flu, nephritis, enuresis, stroke, jaundice, rheumatism, pain relief, various wounds, fever due to inflammation, feverish inflammation of the stomach and intestines, chronic inflammation of the stomach, jaundice, and infectious diseases that is indicated in the textbooks. The Gentiana macrophylla is a medicinal plant that has been studied to some extent within the family of Gentianaceae, but there are many interesting and unexplored issues.
Therefore, in this study, we aimed to investigate skin wound healing activity in experimental rats and determine the median lethal dose (LD₅₀ ) of Gentiana macrophylla pall. The total extract of Gentiana macrophylla pall was extracted by partial maceration with 80% ethanol, thickened and dried, median lethal dose (LD₅₀ ) was determined by the method of V.B. Prozorovski and skin wound healing activity were determined by the method developed by (Mahboobeh Mehrabani Natanzi, 2012).
According to the results of the study, the toxicity of the total dry extract of Gentiana macrophylla was determined to be LD₅₀ =0.397g/kg (0.329g/kg-0.477g/kg), and it was determined that this medicinal plant belongs to the category of less toxic plants. It was found that ointment prepared from the total dry extract of Gentiana macrophylla accelerates the regeneration of intentionally caused wounds in rats and accelerates wound healing.
Based on the results of this research, it has been scientifically established that Gentiana macrophylla supports the regeneration of open wounds and has an important therapeutic value to accelerate healing. In the future, it is necessary to study the mechanism of action of the ointment prepared from the total dry extract of Gentiana macrophylla applied to support wound healing and the activity of other treatments.

Backround: Hematology departments of health laboratories, over capital city and 21 provinces both of governmental and private sectors in this country, have to take responsibilities for providing hematology analysis. A wide range of technology and methods have been implemented among these laboratories. Harmonization of the hematology investigations of different laboratories with standard service all over the country is the major goal to reach. We organized the MEQAS (Mongolian External Quality Assessment Scheme) since 2008 on basis the Cooperation agreement between Ministry of Health and Sysmex Corporation in the establishment of Hematology external quality control and reference laboratory system in Mongolia. This is the report of our 8-year experience of MEQAS as the national project, covering increasing numbers of laboratory members. In 2008-2017 years we set up total 18 MEQAS in Mongolia. Materials and Methods:
Survey Materials
In each survey, the following three different of survey materials were used;
Sample A : Hematology Control Material 1*
Sample B : Hematology Control Material 2*
Sample C : Fresh Whole Blood Sample**
*Hematology Control Material provided by Sysmex Corporation
**Under cooperation of National Center for Transfusiology, a fresh whole blood sample was drawn from a healthy donor and prepared on the same day of sample delivery, according to the procedures reported by Kondo H et. all.
Standard Analyzers
3 units of fully-automated standard analyzers (KX-21, pocH-100i, XS-1000i), installed at the Shastin Central Hospital, were used to assign the target values for the survey materials. These standard analyzers have been calibrated with SCS-1000® before the survey, and monitored with hematology controls, e-CHECK(XS) ® and EIGHTCHECK-3WP® on daily basis.
Instructions & Sample Distribution
On every survey, the workshop was held to give guidance and distribute the survey samples to each participant.
Categorization of Peer Group
Participating data were divided into two peer groups, based on methodology; Group 1: laboratories used automated hematology analyzer (in further Auto’s), Group 2: manually examined group. Each laboratory was given ID number and was asked to analyze these samples 3 times and report the all data and average for CBC 8 parameters.
Statistical Evaluation Method
For individual reports, the results for each participant were evaluated and expressed according to peer group mean and standard deviation index (SDI), Precision index (PI), Absolute evaluation, Scoring system and Target-value evaluation methods (A B C D evaluation). Results:
The Auto’s inter-lab CV% of WBC for fresh whole blood showed decrease from 6.1 to 4.2 comparing with17^th and 18th MEQAS.
The Auto’s Inter-lab CV% of RBC for fresh whole blood showed decrease from 3.7 to 3.4 comparing with 17^th and 18^th MEQAS.
The Auto’s inter-lab CV% of HGB for fresh whole blood were very stable (2.9%, 3.0%), respectively from 17^th to 18^th MEQAS.
The Auto’s inter-lab CV% HCT for the fresh whole blood showed go down from 5.5% to 4.8% comparing with 17^th and 18^th MEQAS.
The Auto’s inter-lab CV% PLT for fresh blood showed go down from 10.2% to 8.2% comparing with 17^th and 18^th MEQAS.
The Auto’s inter-lab CV% of CBC parameter for fresh blood and control Material (Sample A) showed go down from 1^st to 18^th MEQAS.
The Auto’s inter-lab CV% of WBC, RBC, HGB, PLT for Control Material (Sample A) were big difference comparing with Japan’s CV%. Conclusion:
1. The Auto’s inter-lab CV% of WBC, RBC and PLT for fresh whole blood has been decrease respectively 4.2%, 3.4%, 8.2% in the 18^th MEQAS and there was difference in the CV% between manufacturers.
2. The Auto’s inter-lab CV% of WBC, RBC, HGB, PLT for Control Material (Sample A) showed go down from 1^st to 18^th MEQAS but were big difference comparing with Japan’s CV%. Acknowledgements We would like to express our appreciation to the Sysmex Corporation (Japan) for providing financial supports investigate this study.